Outcomes of thrombolytic therapy for acute myocardial infarction in women

Progress in Cardiovascular Diseases

Volumn 47, Issue 1, 2004, Pages 58-71

  Mallik, Susmita ^a   Vaccarino, Viola ^b  

^a Division of General Medicine   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UROKINASE;

ACUTE HEART INFARCTION; AGE; ANGIOCARDIOGRAPHY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY REPERFUSION; DRUG SAFETY; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GENDER; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATEMESIS; HEMATOMA; HEMATURIA; HUMAN; MORTALITY; PATIENT MONITORING; RECURRENT DISEASE; REVIEW; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

EID: 7044237262     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2004.05.001     Document Type: Article

References (99)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. 2001;American Heart Association, Dallas, TX
2. Kudenchuck P.J., Maynard C., Martin J.S., et al. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol. 78:1996;9-14
3. Meischke H., Larsen M.P., Eisenberg M.S. Gender differences in reported symptoms for acute myocardial infarction Impact on pre-hospital delay time interval. Am J Emerg Med. 16:1998;363-366
4. Vaccarino V., Parsons L., Every N.R., et al. Sex-based differences in early mortality after myocardial infarction. N Engl J Med. 341:1999;217-225
5. Hochman J.S., Tamis J.E., Thompson T.D., et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med. 341:1999;226-232
6. Meischke H., Yasui Y., Alan K., et al. How women label and respond to symptoms of acute myocardial infarction Responses to hypothetical symptom scenarios. Heart Lung. 28:1999;261-269
7. Milner K.A., Funk M. Gender Differences in presenting symptoms in patients with coronary heart disease. Circulation. 98:(Suppl 1):1998;I-248
8. Mosca L., Manson J.E., Sutherland S.E., et al. Cardiovascular disease in women A statement for healthcare professionals from the American Heart Association. Circulation. 96:1997;2468-2482
9. Boden W. Defining the optimal pharmacotherapy of non-ST segment elevation acute coronary syndromes A rapidly moving target. Curr Opin Cardiol. 16:2001;370-374
10. Reilly A., Dracup K., Dattolo J. Factors influencing prehospital delay in patients experiencing chest pain. Am J Crit Care. 3:1994;300-306
11. Hochman J.S., McCabe C.H., Stone P.H., et al. Outcome and profile of women and men presenting with acute coronary syndromes A report from TIMI IIIB. J Am Coll Cardiol. 30:1997;141-148
12. Glaser R., Herrmann H., Murphy S.A., et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 288:2002;3124-3129
13. Clarke K.W., Gray D., Keating N.A., et al. Do women with acute myocardial infarction receive the same treatment as men? Br Med J. 309:1994;563-566
14. Lee K.L., Woodlief L.H., Topol E.J., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation. 91:1995;1659-1668
15. Heer T., Schiele R., Schneider S., et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol. 89:(5):2002;511-517
16. Gottlieb S.S., Harpaz D., Avraham S., et al. Sex differences in management and outcome after acute myocardial infarction in the 1990s. A prospective observational community-based study. Circulation. 102:1990;2484-2490
17. Vaccarino V., Krumholz H.M., Yarzebski J., et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 134:2001;173-181
18. Vaccarino V., Horwitz R.I., Meehan T.P., et al. Sex differences in mortality after myocardial infarction Evidence for a sex-age interaction. Arch Intern Med. 158:1998;2054-2062
19. Rosengren A., Spetz C.L., Koster M., et al. Sex differences in survival after myocardial infarction in Sweden; data from the Swedish National Acute Myocardial Infarction Register. Eur Heart J. 22:2001;314-322
20. Fletcher A.P., Alkjaersig N., Smyrniotis F.E., et al. The treatment of patients suffering from acute myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 71:1958;. 287-196
21. Yusuf S., Collins R., Peto R., et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction Overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 6:1985;556-585
22. Rentrop K.P., Blanke H., Karsch K.R., et al. Acute myocardial infarction Intracoronary application of nitroglycerine and streptokinase. Clin Cardiol. 2:1979;354-363
23. White H.D., Van de Werf F. Thrombolysis for acute myocardial infarction. Circulation. 97:1998;1632-1646
24. Verheugt F., Meijer A., Lagrand W., et al. Reocclusion The flip side of coronary thrombolysis. J Am Coll Cardiol. 27:1996;766-773
25. Davies M.J., Thomas A.C. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J. 53:1985;363-373
26. Levine G.N., Ali M.N., Schafer A.I. Antithrombotic therapy in patients with acute coronary syndromes. Arch Intern Med. 161:2001;937-948
27. Ohman E.M., Harrington R.A., Cannon C.P., et al. Intravenous thrombolysis in acute myocardial infarction. Chest. 119:2001;253S-277S
28. Ryan T.J., Anderson J., Antman E., et al. Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 94:1996;2341-2350
29. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 337:1997;1118-1123
30. ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. The ASSENT-2 double-blind randomised trial. Lancet. 354:1999;716-722
31. Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for management of patients with acute myocardial infarction A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 94:1996;2341-2350
32. Committee on Management of Acute Myocardial Infarction. ACC/AHA guidelines for management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 34:1999;890-911
33. Cannon C.P., Battler A., Brindis R., et al. Clinical data standards American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol. 38:2001;2114-2130
34. Stone G.W., Grines C.L., Browne K.F., et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 75:1995;987-992
35. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-402
36. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 2:1988;349-360
37. Wilcox R.G., Olsson C.G., Skene A.M., et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombosis (ASSET). Lancet. ii:1988;525-530
38. White H.D., Barbash G.I., Modan M., et al. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation. 88:1993;2097-2103. (part 1)
39. AIMS (APSAC Intervention Mortality Study) trial study group. Effect of intravenous APSAC on mortality after acute myocardial infarction Preliminary report of a placebo-controlled clinical trial. Lancet. i:1988;545-549
40. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 343:1994;311-322
41. Angeja B.G., Rundle A.C., Gurwitz J.H., et al. Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol. 87:2001;627-630
42. Maggioni A.P., Franzosi M.G., Santoro E., et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med. 327:1992;1-6
43. Maggioni A.P., Maseri A., Fresco C., et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med. 329:1993;1442-1448
44. Maynard C., Litwin P.E., Martin J.S., et al. Gender differences in the treatment and outcome of acute myocardial infarction. Results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med. 152:1992;972-976
45. Lincoff A.M., Califf R.M., Ellis S.G., et al. Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolytic therapy for women with myocardial infarction Is there a gender gap? J Am Coll Cardiol. 22:1993;1780-1787
46. Becker R.C., Terrin M., Ross R., et al. Comparison of clinical outcomes for women and men after acute myocardial infarction. Ann Intern Med. 120:1994;638-645
47. Weaver W.D., White H.D., Wilcox R.G., et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA. 275:1996;777-782
48. Woodfield S.L., Lundergan C.F., Reiner J.S., et al. Gender and acute myocardial infarction Is there a different response to thrombolysis? J Am Coll Cardiol. 29:1997;35-42
49. Murphy S.A., Chen C., Cannon C.P., et al. Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. Am J Cardiol. 90:2002;766-770
50. Lincoff A.M., Califf R.M., Van de Werf F., et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction. JAMA. 288:2002;2130-2136
51. Cannon C.P., McCabe C.H., Diver D.J., et al. Comparisons of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction Results of Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 24:1994;1602-1610
52. Merx W., Dorr R., Rentrop P., et al. Evaluation and effectiveness of intracoronary streptokinase infusion in acute myocardial infarction Post-procedure management and hospital course in 204 patients. Am Heart J. 102:1981;1181-1187
53. Been M., Bono D.P., Muir A.L. Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J. 53:1985;253-259
54. Barbagelata A., Granger C.B., Topol E.J., et al. Frequency, significance and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 76:1995;1007-1013
55. Simoons M.L., Serruys P.W., van den Brand M., et al. Early thrombolysis in acute myocardial infarction Limitation of infarct size and improved survival. J Am Coll Cardiol. 7:1986;717-728
56. The GUSTO-1 Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
57. Brouwer M.A., Bohncke J.R., Veen G., et al. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol. 26:1995;1440-1444
58. Hudson M.P., Granger C.B., Topol E.J., et al. Early reinfarction after fibrinolysis Experience from the Global Utilization of Streptokinase and Tissue plasminogen activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials. Circulation. 104:2001;1229-1235
59. Gore J.M., Granger C.B., Simoons M.L., et al. Stroke after thrombolysis Mortality and functional outcomes in the GUSTO-1 trial. Circulation. 92:1995;2811-2818
60. Kase C.S., Pessin M.S., Zivin J.A., et al. Intracranial hemorrhage following thrombolysis with tissue plasminogen activator. Am J Med. 92:1992;384-390
61. de Jaegere P.P., Arnold A.P., Balk A.H., et al. Intracranial hemorrhage in association with thrombolytic therapy Incidence and predictive factors. J Am Coll Cardiol. 20:1992;289-294
62. Sloan M.A., Sila C.A., Mahaffey K.W., et al. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation. 98:1998;1376-1382
63. Sobel B.E. Intracranial bleeding, fibrinolysis, and anticoagulation Causal connections and clinical implications. Circulation. 90:1994;2147-2152
64. Ickovics J.R., Viscoli C., Horwitz R.I. Functional recovery after myocardial infarction in men The independent effects of social class. Ann Intern Med. 127:1997;518-525
65. Lauer J.E., Heger J.J., Mirro M.J. Hemorrhagic complications of thrombolytic therapy. Chest. 108:1995;1520-1523
66. Gurwitz J.H., Gore J.M., Goldberg R.J., et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 129:1998;597-604
67. Brass L.M., Lichtman J.H., Wang Y., et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction Results from the Cooperative Cardiovascular Project. Stroke. 31:2000;1802-1811
68. Vaccarino V., Chen Y., Wanf Y., et al. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J. 138:1999;835-842
69. Vaccarino V., Lin Z.Q., Kasl S.V., et al. Sex differences in recovery after coronary artery bypass surgery. J Am Coll Cardiol. 41:2003;307-314
70. The ISAM study group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity, and infarct size at 21 days. N Engl J Med. 314:1986;1465-1471
71. Verstraete M., Bory M., Collen D., et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet. ii:1985;842-847
72. Topol E.J., Califf R., George B. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 317:1987;581-588
73. Tracy R.P., Bovill E.G. Fibrinolytic parameters and hemostatic monitoring Identifying and predicting patients at risk of major hemorrhagic events. Am J Cardiol. 69:1992;52A-59A
74. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 339:1992;753-770
75. Califf R.M., Fortin D.F., Tenaglia A.N., et al. Clinical risks of thrombolytic therapy. Am J Cardiol. 69:1992;12A-20A
76. Califf R.M., Topol E.J., George B.S., et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of myocardial infarction. Am J Med. 85:1989;353-359
77. Berkowitz S.D., Granger C.B., Pieper K.S., et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation. 95:1997;2508-2516
78. Granger C.B., Hirsh J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction Results from the GUSTO-I trial. Circulation. 93:1996;870-878
79. Volpi A., de Vita C., Franzosi M.G., et al. Thrombolysis, reperfusion, and survival after myocardial infarcts: Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: Results of the GISSI-2 Data Base. Circulation. 88:1993;416-429
80. Tofler G.H., Stone P.H., Muller J.E., et al. Effect of gender and race on prognosis after myocardial infarction Adverse prognosis for women, particularly black women. J Am Coll Cardiol. 9:1987;473-482
81. Greenland P., Reicher-Reiss H., Goldbourt U., et al. In-hospital and 1-year mortality in 1,524 women after myocardial infarction. Comparison with 4,315 men. Circulation. 83:1991;484-491
82. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622
83. Granger C.B., White H.D., Bates E.R., et al. A pooled analysis of coronary artery patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 74:1994;1220-1228
84. Kostis J.B., Wilson A.C., O'Dowd K., et al. Sex differences in the management and long-term outcome of acute myocardial infarction. Circulation. 90:1994;1715-1730
85. Yarzebski J., Col N., Pagley P., et al. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction A community-wide perspective. Am Heart J. 131:1996;43-50
86. Behar S., Gottlieb S.S., Hod H., et al. The Israel Thrombolytic Survey Group. Influence of gender in the therapeutic management of patients with acute myocardial infarction in Israel. Am J Cardiol. 73:1994;438-443
87. Funk M., Griffey K.A. Relation of gender to the use of cardiac procedures in acute myocardial infarction. Am J Cardiol. 76:1995;226-229
88. Karlson B.W., Hartford M., Herlitz J. Treatment of patients with acute myocardial infarction in relation to gender. Cardiology. 87:1996;230-234
89. Oka R.K., Fortmann S.P., Varady A.N. Differences in treatment of acute myocardial infarction by sex, age, and other factors (the Stanford Five-City Project). Am J Cardiol. 78:1996;861-865
90. Wong C.C., Froelicher E.S., Bacchetti S., et al. Influence of gender on cardiovascular mortality in acute myocardial infarction patients with high indication for coronary angiography. Circulation. 96:(Suppl II):1997;II-51-II-57
91. Barron H.V., Bowlby L.J., Breen T., et al. Use of reperfusion therapy for acute myocardial infarction in the United States. Data from the National Registry of Myocardial Infarction 2. Circulation. 97:1998;1150-1156
92. Mahon N.G., McKenna C.J., Codd M.B., et al. Gender differences in the management and outcome of acute myocardial infarction in unselected patients in thrombolytic era. Am J Cardiol. 85:2000;921-926
93. McLaughlin T.J., Soumerai S.B., Willison D.J., et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction Evidence for undertreatment in women and the elderly. Arch Intern Med. 156:1996;799-805
94. Maynard C., Althouse R., Cerqueira M., et al. Underutilization of thrombolytic therapy in eligible women with acute myocardial infarction. Am J Cardiol. 68:1991;529-530
95. Vermeer F. Thrombolytic therapy in patients of female gender. Thromb Res. 103:2001;S101-S104
96. Canto J.G., Allison J.J., Kiefe C.I., et al. Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. N Engl J Med. 342:2000;1094-1100
97. Bobbio M., Bergerone S., Maggioni A.P., et al. Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction The GISSI-3 database. Am Heart J. 135:1998;443-448
98. Vacek J.L., Handlin L.R., Rosamond T.L., et al. Gender-related differences in reperfusion treatment allocation and outcome for acute myocardial infarction. Am J Cardiol. 76:1995;226-229
99. Chandra N.C., Ziegelstein R.C., Rogers W.J., et al. Observations of the treatment of women in the United States with myocardial infarction a report from the National Registry of Myocardial Infarction-I. Arch Intern Med. 158:1998;981-988